YS BIOPHARMA CO., LTD.

Highlights YS Biopharma Co., Ltd.

Equities

YS

KYG9845F1090

Market Closed - Nasdaq Other stock markets 21:30:01 17/05/2024 BST			5-day change	1st Jan Change
0.9779 ^USD	+2.93%		+0.81%	+91.37%

04-19	YS Biopharma Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2023	CI
04-18	YS Biopharma Receives Clinical Trial Approval for Potential Hepatitis B Treatment	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

YS Biopharma Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2023	04-19	CI
YS Biopharma Receives Clinical Trial Approval for Potential Hepatitis B Treatment	04-18	MT
YS Biopharma Co., Ltd. Grants Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine	04-18	CI
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of Pika Rabies Vaccine	04-09	CI
YS Biopharma Co., Ltd. Reports Earnings Results for the Half Year Ended September 30, 2023	01-22	CI
YS Biopharma Co., Ltd. Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine	31/10/23	CI
YS Biopharma Co., Ltd. Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine	26/09/23	CI
YS Biopharma Says it Obtained US Patent for Immunotherapy Targeting Chronic Hepatitis B; Shares Gain Pre-Bell	15/09/23	MT
Ys Biopharma Co., Ltd. Grants Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infection	15/09/23	CI
YS Biopharma's Pika Rabies Vaccine Receives Phase 3 Clinical Trial Approval from Philippines FDA	01/06/23	CI
YS Biopharma Co., Ltd.'s PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval in Pakistan	16/05/23	CI
YS Biopharma's PIKA Rabies Vaccine Gets Phase 3 Clinical Trial Approval in Pakistan	16/05/23	MT
YS Biopharma Shares Surge 18% Pre-Bell on Estimated Preliminary Revenue for Fiscal Year 2023	18/04/23	MT
YS Biopharma COVID-19 Vaccine Candidate Against Omicron Variant Meets Primary, Secondary Goals	27/03/23	MT
YS Biopharma Co., Ltd. Announces Positive Interim Phase II Safety and Immunogenicity Data for its PIKA Recombinant COVID-19 Vaccine	27/03/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+201.5% on SUPER MICRO COMPUTER since our purchase on February 17, 2023

Replicate our performance

fermer